natgillin/translations-raw huggingface dataset:
The effect of imatinib on the outcome of bone marrow transplantation has not been determined. 
Učinek imatiniba na izid presaditve kostnega mozga ni raziskan.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state. 
Farmakokinetiko imatiniba so ovrednotili v območju odmerjanja od 25 do 1.000 mg. Plazemski farmakokinetični profili so bili analizirani 1. dne, nato pa bodisi 7. bodisi 28. dne, ko so plazemske koncentracije že dosegle stanje dinamičnega ravnovesja.
Table 2 Response in adult CML study 
Preglednica 2 Odziv pri odraslih bolnikih s KML v klinični študiji
In patients with hypereosinophilic syndrome (HES) with occult infiltration of HES cells within the myocardium, isolated cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of imatinib therapy. 
Pri bolnikih s hipereozinofilnim sindromom (HES) z okultno infiltracijo celic HES znotraj miokarda je v posameznih primerih ob uvedbi zdravljenja z imatinibom prišlo, v povezavi z degranulacijo celic HES, do kardiogenega šoka/disfunkcije levega prekata.
Eleven patients achieved rapid CHR; ten had complete resolution of cytogenetic abnormalities and a decrease or disappearance of fusion transcripts as measured by RT-PCR. 
11 bolnikov je doseglo hiter popolni hematološki odziv, pri desetih je prišlo do popolne normalizacije citogenetičnih nepravilnosti in zmanjšanja oziroma izginotja fuzijskih transkriptov, kot so izmerili z verižno reakcijo s polimerazo v realnem času (RT-PCR).
Treatment schedule: On the basis of the existing data, imatinib has been shown to be effective and safe when administered at 600 mg/day in combination with chemotherapy in the induction phase, the consolidation and maintenance phases of chemotherapy (see section 5.1) for patients with newly diagnosed Ph+ ALL. 
Razpored zdravljenja: Na osnovi obstoječih podatkov se je imatinib izkazal kot učinkovito in varno zdravilo, če je bilo pri odraslih bolnikih z novo diagnosticirano Ph+ ALL uporabljeno v odmerku 600 mg/dan v kombinaciji s kemoterapijo v začetni fazi, konsolidacijski in vzdrževalni fazi kemoterapije (glejte poglavje 5.1).
This was not seen at doses ≤ 20 mg/kg. 
Tega pri odmerkih ≤ 20 mg/kg niso opazili.
Patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with imatinib. 
Bolnikom je treba razložiti, da lahko med zdravljenjem z imatinibom doživijo neželene učinke, na primer vrtoglavost, meglen vid ali zaspanost.
Patients with mild and moderate impairment of renal function appear to have a higher plasma exposure than patients with normal renal function. 
Kaže, da je pri bolnikih z blago in zmerno okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic.
Therefore, caution should be recommended when driving a car or operating machinery. 
Zato je treba bolnikom, ki vozijo avto ali uporabljajo stroje, priporočiti previdnost.
This medicine works by inhibiting the growth of abnormal cells in the diseases listed below. 
Zdravilo deluje tako, da zavira rast nenormalnih celic pri spodaj navedenih boleznih, med katerimi so tudi nekatere vrste raka.
There was more myelosuppression seen in CML patients than in GIST, which is probably due to the underlying disease. 
Pri bolnikih s KML je bila mielosupresija izrazitejša kot pri bolnikih z GIST, kar je verjetno posledica osnovne bolezni.
Papilloma/carcinoma of the preputial/clitoral gland were noted from 30 mg/kg/day onwards, representing approximately 0.5 or 0.3 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 times the daily exposure in paediatric patients (based on AUC) at 340 mg/m2/day. 
Papilome/karcinome prepucijske/klitorisne žleze so opazili pri odmerkih od 30 mg/kg/dan naprej, kar predstavlja približno 0,5-kratnik oziroma 0,3-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan, in 0,4-kratnik dnevne izpostavljenosti pediatričnih bolnikov (na podlagi AUC) pri 340 mg/m²/dan.
• adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 
• odraslih bolnikov z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD) v povezavi s preureditvijo genov za receptor za rastni faktor iz trombocitov (PDGFR - platelet derived growth factor receptor),
Disease-free survival (DFS) and overall survival (OS) constantly exceeded 1 year and were superior to historical control (DFS p < 0.001; OS p < 0.0001) in two studies (AJP01 and AUS01). 
V dveh študijah (AJP01 in AUS01) sta preživetje brez bolezni (DSF - disease-free survival) in celokupno preživetje (OS - overall survival) pogosto presegala 1 leto in sta bila daljša kot pri zgodovinskih kontrolah (DFS p < 0,001; OS p < 0,0001).
All patients achieved complete haematological response, cytogenetic response and/or clinical response. 
Pri vseh bolnikih je prišlo do popolnega hematološkega odziva, do citogenetičnega odziva in/ali do kliničnega odziva.
Imatinib medac may cause your body to retain water (severe fluid retention). 
Zaradi zdravila Imatinib medac lahko telo zadržuje vodo (lahko pride do močnega zastajanja tekočine).
These effects were not seen at doses ≤ 30 mg/kg. 
Teh učinkov pri odmerkih ≤ 30 mg/kg niso opazili.
imatinib was administered intermittently in cohorts 1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses). 
Bolnikom v kohortah 1-5 so imatinib odmerjali intermitentno, pri čemer je bilo v vsaki nadaljnji kohorti trajanje zdravljenja daljše, začetek zdravljenja z imatinibom pa zgodnejši, tako da je bila v 1. kohorti intenzivnost zdravljenja z imatinibom najnižja, v 5. kohorti pa najvišja (najdaljše trajanje zdravljenja glede na število dni neprekinjenega enkrat dnevnega odmerjanja imatiniba pri prvem poteku kemoterapije).
The dose of 340 mg/m daily is recommended for children with Ph+ ALL (not to exceed the total dose of 600 mg). 
Za otroke s Ph+ ALL je priporočeni odmerek 340 mg/m na dan (ne sme preseči celotnega odmerka 600 mg).
Maintenance (8-week cycles) Cycles 6-12 
50. dan vzdrževalno zdravljenje (8 tedenski ciklusi) 6.-12. ciklus
• If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, 
• Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Dosing for children should be on the basis of body surface area (mg/m2). 
Odmerjanje pri Ph+ ALL pri otrocih Odmerjanje za otroke mora temeljiti na telesni površini (mg/m2).
The age of these patients ranged from 20 to 72 years. 
Starost teh bolnikov je bila od 20 do 72 let.
Paediatric patients: A total of 26 paediatric patients of age < 18 years with either chronic phase CML (n = 11) or CML in blast crisis or Ph+ acute leukaemias (n = 15) were enrolled in a dose-escalation phase I trial. 
Pediatrični bolniki: V preskušanje stopnjevanja odmerka prve faze so vključili skupaj 26 pediatričnih bolnikov, starih < 18 let, bodisi s kronično fazo KML (n = 11) bodisi s KML v blastni krizi ali Ph+ akutnimi levkemijami (n = 15).
• Myelodysplastic/myeloproliferative diseases (MDS/MPD). 
• z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD).
1) Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST. 
1) O pljučnici so najpogosteje poročali pri bolnikih s transformacijo KML in pri bolnikih z GIST.
The usual starting dose in treatment in CML in blast crisis is 600 mg, to be taken as 6 capsules of 100 mg (or 1 capsule of 400 mg plus 2 capsules of 100 mg) once a day. 
Običajni začetni odmerek pri zdravljenju KML v blastni krizi je 600 mg, odmerek jemljite v obliki 6 kapsul po 100 mg (ali 1 kapsule po 400 mg in 2 kapsuli po 100 mg) enkrat na dan.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started. 
Pred začetkom zdravljenja bo zdravnik skrbno pregledal bolnike glede znakov te
No new target organs were identified in the rat juvenile development toxicology study (day 10 to 70 postpartum) with respect to the known target organs in adult rats. 
Glede na znane tarčne organe pri odraslih podganah niso v toksikološki študiji razvoja mladih podgan (10.-70. dan po skotitvi) ugotovili novih tarčnih organov.
UNIQUE IDENTIFIER - 2D BARCODE {2D barcode carrying the unique identifier included.} 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA <Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.>
RTC: < 15 % blasts BM and PB, < 30 % blasts+promyelocytes in BM and PB, < 20 % basophils in PB, no extramedullary disease other than spleen and liver. 
9/l RTC: < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v
Patients with renal impairment should be given the minimum starting dose. 
Bolniki z okvarjenim delovanjem ledvic naj prejmejo najmanjši priporočeni začetni odmerek.
The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 1.2 times the daily exposure in paediatric patients (based on AUC) at 340 mg/m2/day. 
Adenome/karcinome ledvic, papilome sečnega mehurja in sečnice, adenokarcinome tankega črevesa, adenome obščitničnih žlez, benigne in maligne medularne tumorje nadlevičnih žlez in papilome/karcinome ne-žleznega dela želodca so opazili pri odmerku 60 mg/kg/dan, kar predstavlja približno 1,7 do 1-kratnik dnevne izpostavljenosti človeka (na podlagi AUC) pri odmerku 400 mg/dan oziroma 800 mg/dan in 1,2-kratnik dnevne izpostavljenosti pediatričnih bolnikov (na podlagi AUC) pri 340 mg/m²/dan.
If cytopenia persists for 2 weeks, reduce further to 300 mg. 
Če citopenija vztraja 2 tedna, odmerek zmanjšajte na 300 mg.
Studies on patients receiving imatinib and its effect on fertility and gametogenesis have not been performed. 
Pri ljudeh niso opravili študij z bolniki, ki prejemajo imatinib, da bi preučili vpliv zdravila na plodnost in na gametogenezo.
It should be noted that GIST patients may have hepatic metastases which could lead to hepatic impairment. 
Bolniki z GIST imajo lahko jetrne metastaze, zaradi česar lahko pride do okvare jeter.
What Imatinib medac is and what it is used for 
Kaj je zdravilo Imatinib medac in za kaj ga uporabljamo
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22, 29, 36, 43, 50 
metotreksat (20 mg/m2/teden, peroralno): 8., 15., 22., 29., 36., 43. in
How long to take Imatinib medac Keep taking Imatinib medac every day for as long as your doctor tells you. 
Koliko časa jemati zdravilo Imatinib medac Zdravilo Imatinib medac jemljite vsak dan, dokler vam zdravnik ne naroči, da ga prenehajte jemati.
2) Headache was the most common in GIST patients. 
2) Pri bolnikih z GIST je bil najpogostejši glavobol.
If you forget to take Imatinib medac • If you forget a dose, take it as soon as you remember. 
• Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
In Ph+ ALL patients, there is clinical experience of co-administering imatinib with chemotherapy (see section 5.1), but drug-drug interactions between imatinib and chemotherapy regimens are not well characterised. 
Kljub temu, da klinične izkušnje s sočasno uporabo imatiniba in kemoterapije pri bolnikih s Ph+ ALL obstajajo (glejte poglavje 5.1), pa interakcije med imatinibom in posameznimi kemoterapevtskimi shemami niso dobro opredeljene.
One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. 
V enem odprtem multicentričnem kliničnem preskušanju faze II (študija B2225) so preskušali imatinib pri različnih populacijah bolnikov z življenjsko ogrožujočimi boleznimi v povezavi z Abl, Kit ali PDGFR protein tirozin kinazami.
• Muscle weakness and spasms with an abnormal heart rhythm (signs of changes in the amount of 
• oslabelost mišic in mišični spazmi z nepravilnim ritmom bitja srca (znaki spremenjenih
1200 mg to 1600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite. 
Odmerki od 1200 mg do 1600 mg (trajanje zdravljenja od 1 do 10 dni): navzea, bruhanje, driska, izpuščaj, eritem, edemi, otekanje, utrujenost, mišični spazmi, trombocitopenija, pancitopenija, bolečine v trebuhu, glavobol, zmanjšan tek.
• Do not breast-feed during the treatment with Imatinib medac as there is limited information on the distribution of imatinib into the breast milk. 
• Med zdravljenjem z zdravilom Imatinib medac ne dojite, saj so podatki o prehajanju imatiniba
There are no controlled trials in paediatric patients with DFSP. 
Pri pediatričnih bolnikih z DFSP niso opravili nobenega kontroliranega preskušanja.
9/l, then resume treatment at 300 mg. 
9/l, nato spet začnite zdravljenje z odmerkom 300 mg.
In an oral pre- and postnatal development study in rats, red vaginal discharge was noted in the 45 mg/kg/day group on either day 14 or day 15 of gestation. 
V peroralni študiji predporodnega in poporodnega razvoja pri podganah so pri skupini s 45 mg/kg/dan 14. ali 15. dne brejosti opazili rdeč izcedek iz nožnice.
There was a significant increase in exposure to imatinib (the mean Cmax and AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor). 
Pri zdravih osebah se je izpostavljenost imatinibu značilno povečala (povprečna Cmax in AUC imatiniba sta se povečali za 26 % oziroma 40 %), kadar je bil uporabljen z enim samim odmerkom ketokonazola (zaviralec CYP3A4).
Do not use any pack that is damaged or shows signs of tampering. 
Ne uporabljajte tega zdravila, če opazite, da je škatla poškodovana ali kaže znake, da je bila že odprta.
In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2. 
V toksikološki študiji mladih podgan so opazili zakasnitev odprtja nožnice in ločitve prepucija pri povprečni pediatrični izpostavljenosti, ki je bila 0,3 do 2-krat večja od največjega priporočenega odmerka 340 mg/m².
4) Flushing was most common in GIST patients and bleeding (haematoma, haemorrhage) was most common in patients with GIST and with transformed CML (CML-AP and CML-BC). 
4) Navali rdečice so bili najpogostejši pri bolnikih z GIST, krvavitve (hematomi in krvavitve) pa so bile najpogostejše pri bolnikih z GIST ter pri bolnikih s transformacijo KML (KML-AP in KML-BC).
In the study in patients with unresectable and/or metastatic GIST, both gastrointestinal and intratumoural haemorrhages were reported (see section 4.8). 
V študiji pri bolnikih z neoperabilnim in/ali metastatskim GIST so poročali o krvavitvah iz prebavil in iz tumorja (glejte poglavje 4.8).
At the time of the original analysis, three of the four patients with detected PDGFR gene rearrangements developed haematological response (2 CHR and 1 PHR). 
V času prvotne analize so trije od štirih bolnikov z dokazano preureditvijo gena za PDGFR dosegli hematološki odziv (2 sta dosegla popolni in 1 delni hematološki odziv).
No evidence of leukaemia (NEL) Return to chronic phase (RTC) Major cytogenetic response Complete (Confirmed 
Hematološki odziv Popolni hematološki odziv (CHR) Nobenih znakov levkemije (NEL) Vrnitev v kronično fazo (RTC) Pomemben citogenetični odziv Popoln odziv (Potrjen
• Numbness of the hands or feet. 
• odrevenelost dlani ali stopal,
Imatinib medac is indicated for the treatment of 
Zdravilo Imatinib medac je indicirano za zdravljenje
This Ki value is far higher than the expected plasma levels of imatinib in patients, consequently no interaction is expected upon co-administration of either 5-fluorouracil or paclitaxel and imatinib. 
Ta vrednost Ki je mnogo večja kot pričakovane plazemske koncentracije imatiniba pri bolnikih, zato po sočasnem dajanju bodisi 5-fluorouracila ali paklitaksela in imatiniba ni pričakovati medsebojnega delovanja.
(2 h, q 12 h), days 2-3 (total of 8 courses) 
(2 uri, na 12 ur), 2.-3. dan (skupno 8 kur)
The in vitro results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of imatinib. 
Rezultati in vitro so pokazali, da je pri človeku poglavitni encim P450, ki katalizira biotransformacijo imatiniba, CYP3A4.
10) Musculoskeletal pain and related events were more commonly observed in patients with CML than in GIST patients. 
10) Mišično-skeletne bolečine in z njimi povezane dogodke so pogosteje opažali pri bolnikih s KML kot pri bolnikih z GIST.
Additionally, partial cytogenetic response (PCyR) was observed in 16 % for a MCyR of 81 %. 
Poleg tega so zabeležili tudi delen citogenetični odziv (PCyR) pri 16 % bolnikov ob 81 % s pomembnim citogentičnim odzivom.
It is important that you do this as long as your doctor, pharmacist or nurse tells you to. 
Pomembno je, da zdravilo jemljete tako dolgo, kot vam naroči zdravnik, farmacevt ali medicinska sestra.
• Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain). 
• hud glavobol, oslabelost ali ohromelost okončin ali obraza, težave pri govoru, nenadna izguba zavesti (znaki težav z živčevjem, kot sta krvavitev ali otekanje v lobanjski votlini/možganih),
These are blood diseases in which some blood cells (named eosinophils) start growing out of control. 
To so bolezni krvi, pri katerih se začnejo nenadzorovano razraščati nekatere krvne celice, ki se imenujejo eozinofilci.
In GIST the investigational medicinal product was discontinued for imatinib-related adverse reactions in 4 % of patients. 
Pri bolnikih z GIST so prekinitev zdravljenja z raziskovanim zdravilom zaradi neželenih učinkov, povezanih z imatinibom, zabeležili pri 4 % bolnikov.
Renal insufficiency: Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose. 
Insuficienca ledvic: Bolniki z okvarjenim delovanjem ledvic ali bolniki na dializi naj za začetni odmerek prejmejo najmanjši priporočeni odmerek 400 mg na dan.
• adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. 
• odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFRα ali z obojim,
If you get any of the above, tell your doctor straight away. 
Če opazite katerega od zgoraj navedenih neželenih učinkov, nemudoma obvestite zdravnika.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. 
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF-plateletderived growth factor), PDGF-R in dejavnik matičnih celic (SCF-stem cell factor), c-Kit, in zavira celične dogodke, ki jih posredujeta PDGF in SCF.
Additionally, improvements in symptomatology and other organ dysfunction abnormalities were reported by the investigators in the case reports. 
Poleg navedenega so raziskovalci v opisih primerov poročali tudi o izboljšanju simptomatike in nepravilnosti delovanja drugih organov.
Posology for HES/CEL in adult patients 
Odmerjanje pri HES/CEL pri odraslih bolnikih
Relapsed/refractory Ph+ ALL: When imatinib was used as single agent in patients with relapsed/refractory Ph+ ALL, it resulted, in the 53 out of 411 patients evaluable for response, in a haematological response rate of 30 % (9 % complete) and a major cytogenetic response rate of 23 %. 
Relaps/neodzivna Ph+ ALL: Zdravljenje z imatinibom kot edinim zdravilom pri bolnikih z relapsom/neodzivno Ph+ ALL je povzročilo pri 53 od 411 za oceno odziva primernih bolnikov stopnjo hematološkega odziva 30 % (v 9 % popolni hematološki odziv) in stopnjo pomembnega citogenetičnega odziva 23 %.
Triple IT therapy (age-adjusted): day 1 
zdravljenje (prilagojeno na starost): 1. dan
Dosing in paediatric patients at 260 and 340 mg/m2/day achieved the same exposure, respectively, as doses of 400 mg and 600 mg in adult patients. 
Odmerek 260 oziroma 340 mg/m² pri pediatričnih bolnikih je dosegel enako izpostavljenost kot odmerek 400 mg oziroma 600 mg pri odraslih bolnikih.
Dose increases from 600 mg to a maximum of 800 mg (given as 400 mg twice daily) in patients with blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukaemia-related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time); failure to achieve a satisfactory haematological response after at least 3 months of treatment; failure to achieve a cytogenetic response after 12 months of treatment; or loss of a previously achieved haematological and/or cytogenetic response. 
Povečanje odmerka s 600 mg na največ 800 mg (ki se daje kot 400 mg dvakrat na dan) pri bolnikih v blastni krizi lahko pride v poštev, če bolnik nima hude neželene reakcije na zdravilo in hude nevtropenije ali trombocitopenije, ki ni povezana z levkemijo, v naslednjih okoliščinah: napredovanje bolezni (kadarkoli); odsotnost zadovoljivega hematološkega odziva po najmanj 3 mesecih zdravljenja; odsotnost citogenetičnega odziva po 12 mesecih zdravljenja; ali izguba že prej doseženega hematološkega in/ali citogenetičnega odziva.
Multiple dose toxicity studies revealed mild to moderate haematological changes in rats, dogs and monkeys, accompanied by bone marrow changes in rats and dogs. 
Študije toksičnosti ponavljajočih se odmerkov so pokazale blage do zmerne hematološke spremembe pri podganah, psih in opicah.
340 mg/m daily is recommended for paediatric patients with chronic phase CML and accelerated phase CML (not to exceed the total dose of 800 mg). 
Za pediatrične bolnike s kronično fazo KML oziroma s pospešeno fazo KML je priporočeni odmerek 340 mg/m² na dan (ne sme preseči celotnega odmerka 800 mg).
Newly diagnosed Ph+ ALL: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55 newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3 % vs. 50 %; p = 0.0001). 
Novo odkrita Ph+ ALL: V kontrolirani študiji (ADE10) imatiniba v primerjavi z indukcijo s kemoterapijo pri 55 bolnikih z novo odkrito boleznijo, ki so bili stari 55 let ali več, je imatinib kot edino zdravilo povzročil značilno večji delež bolnikov s popolnim hematološkim odzivom kot kemoterapija (96,3 % v primerjavi s 50 %; p = 0,0001).
Other medicines and Imatinib medac 
Druga zdravila in zdravilo Imatinib medac
The age of these patients ranged from 25 to 72 years. 
Ti bolniki so bili stari od 25 do 72 let.
Ara-C 1,000 mg/m2/12 h i.v. 
Ara-C 1.000 mg/m²/12 ur i.v.
Active substances that may have their plasma concentration altered by imatinib Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, indicating an inhibition of the CYP3A4 by imatinib. 
Učinkovine, katerih plazemske koncentracije lahko imatinib spremeni Imatinib povečuje povprečno Cmax in AUC simvastatina (substrat CYP3A4) 2-krat oziroma 3,5-krat, kar kaže na to, da imatinib zavira CYP3A4.
• Anorexia, weight loss or a disturbed sense of taste. 
• izguba apetita, zmanjšanje telesne mase ali moten občutek za okus,